
First patient dosed in phase 2 study for the treatment of hospitalized patients with acute lung injury caused by covid-19
The initiation of the Phase 2 study in patients in the United Kingdom (UK) follows the successful completion of dosing in the Phase 1 study in healthy volunteers at the same clinical unit in the UK, allowing for a rapid transition to Phase 2.